Clay Siegall, Ph.D., is perhaps best known as a scientist and the co-founder of the company known as Seattle Genetics. He co-launched it back in 1998. At present, he works as the firm’s CEO, (chief executive officer), president, and current chairman of the board.
Siegall is reported to be especially knowledgeable in the subjects of “targeted cancer therapies.” He is also said to be passionate about assisting his patients. In fact, he co-founded Seattle Genetics on the tenants of research, scientific innovation, and various drug development practices.
Siegall’s business is at the forefront when it comes to developing antibody-drug conjugates (ADC) and in garnering Food and Drug Administration (FDA) approval for brentuximab vedotin (Adcetris), the firm’s first official ADC product, back in 2011.
Siegall and his team partnered with Takeda Pharmaceutical Company in order to create Adcetris. It’s now an international brand that has been approved for use in more than 60 nations. Additionally, they are busy developing several proprietary ADCs for the treatment of cancer.
Seattle Genetics has a few licenses for their ADC technology too. They have brought in more than $325 million with GlaxoSmithKline, Pfizer, Genentech (Roche), and AbbVie. There are now over 20 ADCs presently being developed through SG’s technology. Siegall is said to be the person responsible for the firm’s money-raising efforts which resulted in a total of approximately $1.2 billion via public and private sources like their IPO (initial public offering) which debuted in 2001.
Siegall graduated with a Ph.D. in Genetics from GWU (George Washington University.) Prior to the launch of Seattle Genetics, he worked at the Bristol-Myers Squibb Pharmaceutical Research Institute (1991 to 1997.) He was also previously employed by NCI (the National Cancer Institute) and NIH (National Institutes of Health) from 1988 to 1991.
Doctor Siegall has received several different awards including the famous 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Currently, Siegall has a seat on multiple Boards of Directors at such companies as Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and the Washington Roundtable.